Holen Sie sich die Stockscreener-App
0.7739
1.69%
-0.0133
Schlusskurs vom Vortag:
$0.7872
Offen:
$0.785
24-Stunden-Volumen:
305.28K
Relative Volume:
0.32
Marktkapitalisierung:
$43.20M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-33.36M
KGV:
-1.154
EPS:
-0.6706
Netto-Cashflow:
$-23.09M
1W Leistung:
-9.28%
1M Leistung:
-26.99%
6M Leistung:
-27.67%
1J Leistung:
-40.47%
1-Tages-Spanne:
$0.7403
$0.7936
1-Wochen-Bereich:
$0.7403
$0.89
52-Wochen-Spanne:
$0.5068
$1.55
Pds Biotechnology Corp Stock (PDSB) Company Profile
Firmenname
Pds Biotechnology Corp
Sektor
Branche
Telefon
800-208-3343
Adresse
303A COLLEGE ROAD EAST, PRINCETON
Compare PDSB vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corp
|
0.7739 | 43.20M | 0 | -33.36M | -23.09M | -0.6706 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pds Biotechnology Corp Stock (PDSB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-11-01 | Eingeleitet | B. Riley Securities | Buy |
| 2021-06-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-11-10 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-05-27 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-03-09 | Eingeleitet | Noble Capital Markets | Outperform |
| 2019-10-24 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Pds Biotechnology Corp Aktie (PDSB) Neueste Nachrichten
PDS Biotechnology (NASDAQ: PDSB) registers 13.3M shares tied to note and warrant deal - Stock Titan
PDSB | PDS Biotechnology Corporation Common Executive Compensation - Quiver Quantitative
PDS Biotechnology Corp (PDSB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
PDS Biotechnology (NASDAQ: PDSB) details 2026 proxy votes and pay - Stock Titan
PDS Biotechnology Corp. Actuals & Estimates (NASDAQ:PDSB) - TradingView
PDS Biotechnology Corp. Actuals & Estimates (DUS:EU6) - TradingView
PDSB Forecast — Price Target — Prediction for 2027 - TradingView
PDS Biotech’s Double Squeeze: Nasdaq Clock Ticking as Equity Dilution Looms - AD HOC NEWS
PDS Biotechnology Corp (PDSB) Institutional Confidence - TradingKey
PDS Biotechnology Corp (PDSB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
PDS Biotechnology Corp (PDSB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
PDS Biotechnology Corp (PDSB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PDS Biotechnology Corp (PDSB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PDS Biotechnology Corp (PDSB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
PDS Biotechnology Corp (PDSB) Valuation: PE, PB & Fair Value Analysis - TradingKey
PDS Biotechnology Closes Financing and Retires Convertible Debentures - TipRanks
PDS Biotechnology (NASDAQ: PDSB) launches $50M ATM program tied to YA II financing - Stock Titan
[PRE 14A] PDS Biotechnology Corp Preliminary Proxy Statement - Stock Titan
PDS Biotechnology (NASDAQ: PDSB) adds $6M note and $50M at-the-market stock program - Stock Titan
PDS Biotechnology schedules 2026 annual meeting for Aug. 10; stockholder proposal deadline set - TradingView
PDS Biotechnology (PDSB) schedules 2026 annual meeting and sets June 25 proposal cutoff - Stock Titan
PDSB Q1 2026 Earnings: EPS Beat Fails to Lift Shares as Pipeline Progress AwaitedROA Comparison - dars.gov.et
Here's Why PDS Biotechnology (PDSB) Could be Great Choice for a Bottom Fisher - MSN
Should I buy PDS Biotechnology (PDSB) - Zacks Investment Research
PDS Biotechnology Corporation - MLQ.ai
PDS Biotechnology Stock Gets Nasdaq Extension as Traders Eye PDSB - Bez Kabli
PDS Biotechnology (NASDAQ: PDSB) back in compliance with Nasdaq $1.00 bid rule - Stock Titan
PDS Biotechnology (PDSB) Slides 3.6% as Stock Tests Key Support Near $1.02Breakaway Gap - The Legal Advocate
PDSBPDS Biotechnology Corp Stock Price and Quote - Finviz
PDSB Q4 2025 Earnings Call Transcript - Yahoo Finance
PDS Biotechnology Q1 2026 Earnings: EPS Beat on Narrower Loss, Clinical Progress in FocusReturn On Capital - Newser
PDS Biotechnology Q1 2026 Earnings: Narrowed Loss Per Share and Clinical Progress Drive Positive Market ResponseGrowth Acceleration Report - thelegaladvocate.com
PDS Biotechnology Q1 2026 Earnings: Narrower-than-Expected Loss Drives Stock Up 3.45%Earnings Growth Forecast - Newser
PDS Biotechnology Q1 2026 Earnings: EPS Beat Highlights Progress Despite Pre-Revenue StatusEarnings Forecast Report - newsline.com
PDS (PDSB) Q1 2026 Beat: Revenue $N/A, EPS Exceeds by SignificantPositive Surprise Momentum - The Legal Advocate
ETFs Investing in PDS Biotechnology Corp. Stocks - TradingView
PDS Biotechnology Q1 2026 earnings preview - MSN
Number of shareholders of PDS Biotechnology Corp. – SWB:EU6 - TradingView
PDS Biotechnology: Juni-Test für Wandelanleihe - kapitalmarktexperten.de
PDSB Stock Price, Quote & Chart | PDS BIOTECHNOLOGY CORP (NASDAQ:PDSB) - ChartMill
PDS Biotechnology Corp reports results for the quarter ended March 31Earnings Summary - TradingView
PDS Biotechnology (PDSB) posts Q1 2026 loss and plans costly debt redemption - Stock Titan
PDS Biotechnology Q1 2026 Earnings Call: Complete Transcript - Sahm
PDS Biotech outlines VERSATILE-003 amendment targeting interim PFS with approximately 250 patients - MSN
PDSB Q1 2026 Earnings Transcript - AOL.com
PDS Biotechnology Q1 Earnings Call Highlights - MarketBeat
PDS Biotechnology Corporation Q1 2026 Earnings Call Summary - Yahoo Finance
PDS Biotech Reports Q1 2026 Financial Results, Highlights Clinical Progress in Cancer Immunotherapy Trials - Minichart
Earnings call transcript: PDS Biotechnology beats Q1 2026 EPS expectations By Investing.com - Investing.com South Africa
PDSB: Protocol changes accelerate clinical timelines and reduce costs, with improved financials - TradingView
Earnings call transcript: PDS Biotechnology beats Q1 2026 EPS expectations - Investing.com
Finanzdaten der Pds Biotechnology Corp-Aktie (PDSB)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):